GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Cyclically Adjusted PS Ratio

Vertex Pharmaceuticals (WBO:VRTX) Cyclically Adjusted PS Ratio : 20.74 (As of May. 19, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-19), Vertex Pharmaceuticals's current share price is €407.00. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €19.62. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 20.74.

The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

WBO:VRTX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.8   Med: 27.06   Max: 43.87
Current: 21.07

During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 43.87. The lowest was 14.80. And the median was 27.06.

WBO:VRTX's Cyclically Adjusted PS Ratio is ranked worse than
82.94% of 510 companies
in the Biotechnology industry
Industry Median: 5.555 vs WBO:VRTX: 21.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €9.480. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €19.62 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.16 23.88 17.19 17.86 20.54

Vertex Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.36 19.42 18.20 20.54 19.78

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=407.00/19.62
=20.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.48/131.7762*131.7762
=9.480

Current CPI (Mar. 2024) = 131.7762.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.436 100.560 0.571
201409 0.588 100.428 0.772
201412 0.491 99.070 0.653
201503 0.534 99.621 0.706
201506 0.615 100.684 0.805
201509 1.141 100.392 1.498
201512 1.579 99.792 2.085
201603 1.466 100.470 1.923
201606 1.571 101.688 2.036
201609 1.505 101.861 1.947
201612 1.774 101.863 2.295
201703 2.687 102.862 3.442
201706 1.925 103.349 2.454
201709 1.938 104.136 2.452
201712 2.146 104.011 2.719
201803 2.010 105.290 2.516
201806 2.490 106.317 3.086
201809 2.588 106.507 3.202
201812 2.944 105.998 3.660
201903 2.920 107.251 3.588
201906 3.206 108.070 3.909
201909 3.311 108.329 4.028
201912 4.850 108.420 5.895
202003 5.203 108.902 6.296
202006 5.139 108.767 6.226
202009 4.945 109.815 5.934
202012 5.117 109.897 6.136
202103 5.530 111.754 6.521
202106 5.703 114.631 6.556
202109 6.494 115.734 7.394
202112 7.140 117.630 7.999
202203 7.385 121.301 8.023
202206 8.031 125.017 8.465
202209 9.085 125.227 9.560
202212 8.351 125.222 8.788
202303 8.521 127.348 8.817
202306 8.837 128.729 9.046
202309 8.930 129.860 9.062
202312 8.852 129.419 9.013
202403 9.480 131.776 9.480

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (WBO:VRTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (WBO:VRTX) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.